Background Eisenmenger syndrome (ES) is a severe and fatal complication of uncorrected congenital heart disease characterised ...

The gene therapy market for ocular rare diseases is expanding rapidly as breakthroughs in viral vectors (like AAV) and gene-editing tools enable one-time, disease-modifying treatments for previously ...

Although some outcomes showed small to medium effect sizes, these results must be interpreted cautiously given the presence of uncertainty factors, including considerable heterogeneity and moderate ...

The owner of LED-light therapy mask CurrentBody--which listed on the London Stock Exchange last month--on Wednesday attributed its performance to an ever-increasing awareness of the at-home ...

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory ...

Chris Hemsworth discovered something alarming a few years ago: The same DNA that helped the Australian actor achieve the ...

The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...

Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC)—a leading research partner of the NCI-designated ...

A major new clinical trial involving more than 1,600 people has found that a GLP-1 pill form of the drug orforglipron works ...

(Reuters) -Australian biotech firm CSL said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its footprint in the North American country ...

Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia) delivered sustained ...

Q3 2025 Earnings Call Transcript November 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...